Peptides
Evidence: animal_plus_anecdotal
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is an orally active, blood-brain barrier-permeable oligopeptide derived from angiotensin IV. It binds hepatocyte growth factor (HGF) with high affinity, inhibiting HGF dimerization and synergistically promoting c-Met receptor phosphorylation and signaling. Activation of HGF/c-Met drives procognitive effects through increased dendritic arborization, spinogenesis, and synaptogenesis via the PI3K/AKT signaling pathway. Research indicates it is approximately 10 million times more potent than BDNF for new synapse formation.
Standard: Research indicates 10-20 mg daily via oral or sublingual administration.
Maintenance: Research indicates 10 mg daily or every other day.
Administration: oralsublingualsubcutaneousintranasal
Timing: Morning dosing preferred. Can be taken with or without food (orally active).
Duration: 2-4 week cycles with equal rest periods. Long-term safety data is extremely limited.
Dihexa is one of the most potent nootropic compounds studied, but carries significant theoretical risk due to HGF/c-Met pathway activation — this same pathway is implicated in multiple cancers. The cancer concern is not trivial and should be discussed thoroughly with any client considering Dihexa. Community reports note dramatic improvements in memory formation and emotional depth. The compound was developed at Washington State University for Alzheimer's research. Oral Dihexa (2 mg/kg) reversed scopolamine-induced cognitive deficits in rats within 7 days. Use with extreme caution and only in clients with no cancer history.
Research-grade supplier only. Not available through standard compounding pharmacies. Requires careful sourcing with third-party testing.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →